A phase IIb proof of concept trial investigating the effects of GBT-440 on oxygen saturation in patients with idiopathic pulmonary fibrosis (IPF)

Trial Profile

A phase IIb proof of concept trial investigating the effects of GBT-440 on oxygen saturation in patients with idiopathic pulmonary fibrosis (IPF)

Withdrawn prior to enrolment
Phase of Trial: Phase II

Latest Information Update: 23 Oct 2017

At a glance

  • Drugs Voxelotor (Primary)
  • Indications Idiopathic pulmonary fibrosis
  • Focus Therapeutic Use
  • Most Recent Events

    • 23 Oct 2017 Status changed from planning to withdrawn prior to enrolment according to a Global Blood Therapeutics media release.
    • 23 Oct 2017 According to a company media release, Global Blood Therapeutics has announced the discontinuation of its GBT440 program for the treatment of idiopathic pulmonary fibrosis (IPF). This decision is based on results from three proof-of-concept studies, including a Phase 1 study in healthy volunteers called Basecamp and two Phase 2a studies in patients with IPF called GBT440-006 and ZEPHYR.
    • 05 Apr 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top